Freshfields’ Litigation Team successfully represented Sumitovant Biopharma Limited. A shareholder’s attempt to challenge a $2.9 billion take-private merger between Sumitovant Biopharma Limited (Sumitovant, formerly known as...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here